Login to Your Account



First Deal for Apeiron a Doozy: Getting up to $329M from GSK

By Cormac Sheridan


Wednesday, February 10, 2010
Apeiron Biologics AG licensed its lead program APN01, a recombinant form of human angiotensin converting enzyme 2 (ACE2), to London-based GlaxoSmithKline plc in a deal valued at up to €236 million (US$329.4 million). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription